Long-term follow-up of patients supported with the HeartWare left ventricular assist system.
Adult
Aged
Female
Follow-Up Studies
Gastrointestinal Hemorrhage
/ epidemiology
Heart Failure
/ mortality
Heart Transplantation
/ statistics & numerical data
Heart-Assist Devices
/ adverse effects
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Postoperative Hemorrhage
/ epidemiology
Retrospective Studies
Survival Rate
Treatment Outcome
ECLS
LVAD
heart failure
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
18
08
2019
revised:
04
02
2020
accepted:
19
03
2020
pubmed:
28
3
2020
medline:
12
10
2021
entrez:
28
3
2020
Statut:
ppublish
Résumé
The aim of the present study is to report our long-term experience with the HeartWare Ventricular Assist System (HVAD). Between July 2009 and February 2018, a total of 103 patients (mean age 50.0 ± 14.4, range 28-74 years; 22 females) received HVAD implantation in a single center institution. A total of 26 (25.4%) patients were in cardiogenic shock preoperatively and received extracorporeal life support (ECLS) prior to HVAD implantation. The aim of left ventricular assist device (LVAD) implantation was bridge to transplantation (BT) in 59 (57.3%), destination therapy (DT) in 28 (27.2%), and bridge to decision in 16 (15.5%). There were 211.1 total patient years of support. Mean survival was 2.05 ± 2.14 years. Kaplan-Meier analysis showed an overall survival rate of 69.7%, 56.7%, 46.0%, and 25.0% at 1, 2, 4, and 8 years, respectively. A total of 23 patients (22.3%) died during the hospital stay. Of them 65.2% (15 patients) were preoperatively in cardiogenic shock (INTERMACS 1). Sub-analysis of the BT patients showed a mean survival of 2.45 ± 2.29 years with a survival rate of 85.1%, 75.1%, 67.2%, and 44.8% at 1, 2, 4, and 8 years, respectively. Among them, 20 patients received heart transplantation on follow-up. Mean survival of DT patients was 2.18 ± 1.91 years with a survival rate of 67.9%, 49.0%, and 25.1% at 1, 2, and 4 years, respectively. At latest follow-up in September 2018, 26 patients (25.24%) were still on LVAD. A total of five patients completed 6 years on LVAD, of them two were supported over 8 years. The most common adverse event reported was gastrointestinal bleeding requiring rehospitalization (0.161 EPPY). A total of 19 patients reported disabling stroke. Pump thrombosis was diagnosed in six patients (5.8%) (0.02 EPPY), of them four patients underwent pump exchange. To the best of our knowledge, this is the longest experience with HVAD reported so far. Patients supported with an HVAD show a satisfactory long-term survival. Further multicenter evaluations are needed to confirm these single-center results.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1066Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. Artificial Organs published by International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.
Références
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Heart J. 2016 July 14;37:2129-200.
Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34:1495-504.
Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, et al. MOMENTUM 3 investigators. A fully magnetically levitated a.circulatory pump for advanced heart failure. N Engl J Med. 2017;376:440-50. https://doi.org/10.1056/NEJMoa1610426.
Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, et al. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation. 2017 May 23;135:2003-12. https://doi.org/10.1161/CIRCULATIONAHA.117.028303. Epub 2017 Apr 6.
Beckmann A, Meyer R, Lewandowski J, Frie M, Markewitz A, Harringer W. German heart surgery report 2017: the annual updated registry of the German society for thoracic and cardiovascular surgery. Thorac Cardiovasc Surg. 2018 November;66:608-21. https://doi.org/10.1055/s-0038-1676131. Epub 2018 Dec 3.
Strueber M, Larbalestier R, Jansz P, Zimpfer D, Fiane AE, Tsui S, et al. Results of the post-market registry to evaluate the HeartWare left ventricular assist system (ReVOLVE). J Heart Lung Transplant. 2014;33:486-91.
Wieselthaler GM, O′Driscoll G, Jansz P, Khaghani A, Strueber M. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multiinstitutional trial. J Heart Lung Transplant. 2010;29:1218-25.
Holman WL, Pae WE, Teutenberg JJ, Acker MA, Naftel DC, Sun BC, et al. Kirklin JKINTERMACS: interval analysis of registry data. J Am Coll Surg. 2009 May;208(5):755-61.
Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM, et al. EACTS expert consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019 August 1;56:230-70. https://doi.org/10.1093/ejcts/ezz098.
Tsyganenko D, Gromann TW, Schoenrath F, Mueller M, Mulzer J, Starck C, et al. Predictors of mid-term outcomes in patients undergoing implantation of a ventricular assist device directly after extracorporeal life support. Eur J Cardiothorac Surg. 2019 April 1;55:773-9. https://doi.org/10.1093/ejcts/ezy351.
Tsiouris A, Paone G, Nemeh HW, Borgi J, Williams CT, Lanfear DE, et al. Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices. World J Cardiol 2015;7:792-800.
Hanke JS, Rojas SV, Mahr C, Schmidt A-F, Zoch A, Dogan G, et al. Five-year results of patients supported by HeartMate II: outcomes and adverse events. Eur J Cardiothorac Surg. 2018 February 1;53:422-7. https://doi.org/10.1093/ejcts/ezx313.
Schmitto JD, Zimpfer D, Fiane AE, Larbalestier R, Tsui S, Jansz P, et al. Long-term support of patients receiving a left ventricular assist device for advanced heart failure: a follow-up analysis of the registry to evaluate the HeartWare Left Ventricular Assist System. Eur J Cardiothorac Surg. 2016 November;50:834-8. Epub 2016 Jul 14.